Genezen’s Post

🌟 Exciting News! 🌟   The June Edition of BioProcess International has published a new article featuring Pamela Whalley, Associate Director CMC, on the topic presented at Advanced Therapies in Miami, earlier this year: Partnering for Gene Therapy Manufacturing - What is the Key to Success?   In this insightful piece, Pam explores the crucial factors that gene therapy developers must consider when selecting a CDMO (Contract Development and Manufacturing Organization) and highlights the importance of demanding a pilot study to ensure success.   Read the full article here: https://lnkd.in/gynu-mnA   #GeneTherapy #Biotech #CDMO #Pharmaceuticals #BioProcess #ManufacturingSuccess #HealthcareInnovation #BPI #CMC #complement #conference

The cell and gene therapy field is booming, but making these life-changing treatments accessible remains a challenge. How can we overcome cost barriers and manufacturing hurdles? Cell and gene therapy manufacturing relies heavily on pen and paper, hindering data sharing and slowing down processes. This can be life-threatening for patients who need timely treatment. We need to embrace digital solutions, both inside and outside the cleanroom, to improve efficiency and ensure patient safety. 👉 Read Clinical Trials Arena's article for expert insights from Autolomous CEO Alexander Seyf, David Smith - BioCentriq, John W. Hadden II - ViroCell Biologics, and Romain du Hecquet de Rauville - EXO Biologics

This article highlights some long term predictions about the cell and gene therapy industry, with insights offered by two experts at Cytiva. https://bit.ly/47PIiFy #biotech #pharma #SearchGSS #GSS #biologics #lifesciences #celltherapy #genetherapy

Great insights from Life Science Connect on things to consider when licensing cell and gene therapies. To this we would add that having a strong foundation for commercial manufacturing is a must. To ensure process understanding and ability to scale up to commercially relevant yields, consider running a DoE early in your process. #processdevelopment #processoptimization #AAV #viralvectors

Are you looking to increase the characterization and understanding of your gene therapy products? Join us at the 3-day "Gene Therapy CMC and Manufacturing track" at the Bioprocessing Summit, August 19-22, at Sheraton Boston, to unlock the potential of advanced analytics in ensuring product quality and consistency. https://lnkd.in/dGbQzqv Reasons to Attend: - Navigate comparability challenges in gene therapy with Phillip Ramsey from Sangamo Therapeutics, Inc. and Xiaohui Lu, Ultragenyx Pharmaceutical - Optimize your analytics for AAV characterization with santoshkumar khatwani L. Khatwani, Sangamo Therapeutics - Investigate cutting-edge mass spectrometry techniques with @jonathan Bones, NIBRT National Institute for Bioprocessing Research and Training - Benchmark against the latest RT-MALS applications in biologics and vaccines from Daniel Some, Waters | Waters | Wyatt Technology - Evaluate high-throughput AAV quantification methods with Xueyuan Liu, Childrens Hospital of Philadelphia This session forms part of the "Gene Therapy CMC and Analytics track at ‘Bioprocessing Summit’, and is one of 14 full conference programs at the 2024 Bioprocessing Summit in Boston on August 19-22. These programs cover a wide range of themes, including AI and Digitalization, Cell Therapy, Upstream and Downstream Processing. Join us at the Bioprocessing Summit for a ground-breaking event featuring 1,500 biomanufacturing experts across: 14 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐓𝐫𝐚𝐜𝐤𝐬 including a new stream on "AI and Digitalization" 300+ 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧𝐬 across the spectrum of biologics, gene, cell, and mRNA therapies 90 𝐄𝐱𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 showcasing innovative bioprocessing technologies and services 100+ 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐨𝐬𝐭𝐞𝐫𝐬 revealing the latest in biomanufacturing and analytics 𝐓𝐰𝐨 𝐏𝐥𝐞𝐧𝐚𝐫𝐲 𝐒𝐞𝐬𝐬𝐢𝐨𝐧𝐬 tackling the current and future challenges in bioprocessing #chibioprocessing

In this article, we hear the thoughts of 4 individuals, on the topic of Industry 4.0, in relation to cell and gene therapy. #industry4point0 #cellandgenetherapy #cgt #biopharmaceuticals #biotherapeutics https://lnkd.in/eQ6vuMrj

Are you striving to refine your AAV gene therapy production processes? Facing challenges with scale-down models, production robustness, or raw material variability? Join us at the Bioprocessing Summit, on August 19-22 at Sheraton Boston, to gain strategic insights from 200+ leading viral vector experts. https://lnkd.in/e84zYGj3 Reasons to Attend: - Understand experimental strategies with Dan Odenwelder, Biogen Explore the impact of adherent to suspension transitions with Shaoying Wang, Passage Bio - Discover novel capsid development approaches to enhance commercial viability with Davide Gianni, Biogen - Learn robust producer cell line development strategies from Amit Mathur, Ph.D., Sanofi - Enhance volumetric titers using high-throughput methods with Julien Robitaille, National Research Council Canada Implement cost-effective strategies for clinical development with Frank Agbogbo, Forge Biologics This session forms part of the '2024 Bioprocessing Summit' and is one of 14 full conference programs at the 2024 #chibioprocessingsummit in Boston on August 19-22. These programs cover a wide range of themes, including AI and Digitalization, Cell Therapy, Upstream and Downstream Processing. Join us at the Bioprocessing Summit for a ground-breaking event featuring 1,500 biomanufacturing experts across: 14 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐓𝐫𝐚𝐜𝐤𝐬 including a new stream on "AI and Digitalization" 300+ 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧𝐬 across the spectrum of biologics, gene, cell, and mRNA therapies 90 𝐄𝐱𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 showcasing innovative bioprocessing technologies and services 100+ 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐨𝐬𝐭𝐞𝐫𝐬 revealing the latest in biomanufacturing and analytics 𝐓𝐰𝐨 𝐏𝐥𝐞𝐧𝐚𝐫𝐲 𝐒𝐞𝐬𝐬𝐢𝐨𝐧𝐬 tackling the current and future challenges in bioprocessing

Here are some key takeaways from the American Society of Gene & Cell Therapy's 2024 annual meeting, focusing on AAV manufacturing, gene editing and the emerging trend for accelerated approval as a regulatory pathway.

Here are some key takeaways from the American Society of Gene & Cell Therapy's 2024 annual meeting, focusing on AAV manufacturing, gene editing and the emerging trend for accelerated approval as a regulatory pathway.

Here are some key takeaways from the American Society of Gene & Cell Therapy's 2024 annual meeting, focusing on AAV manufacturing, gene editing and the emerging trend for accelerated approval as a regulatory pathway.